- Home
- BCAX
BCAX
BICARA THERAPEUTICS INC
as 04-18-2025 1:31pm EST
Stocks
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 670.9M | IPO Year: | 2024 |
| Target Price: | $29.67 | AVG Volume (30 days): | 516.6K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.91 - $28.09 | Next Earning Date: | 05-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BICARA THERAPEUTICS INC News
BCAX Breaking Stock News: Dive into BCAX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target
GlobeNewswire
23 days ago
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
25 days ago
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Simply Wall St.
a month ago
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth
GlobeNewswire
2 months ago
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
2 months ago
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
MT Newswires
2 months ago
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target
GlobeNewswire
3 months ago
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Compare BCAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCAX BICARA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.